Paolo Galleri

Dr. Paolo Galleri


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
AMAndrea Marongiu
Andrea Marongiu
PGPaolo Galleri
Paolo Galleri
AMAntonio Mura
Antonio Mura
PSPaolo Solla
Paolo Solla
GMGiuseppe Madeddu
Giuseppe Madeddu
Susanna Maria Francesca NuvoliSusanna Maria Francesca Nuvoli
Susanna Maria Francesca Nuvoli
Background/Objectives: Recent studies reported that 18F-Fluorodeoxyglucose (FDG) positron –emission tomography/computed tomography (PET/CT), even in comparison with other traditional methods, can play a role in diagnosing AE and supporting early treatment. In the present study, we further investigated whether 18F-FDG PET/CT may be a complementary diagnostic tool to conventional procedures in patients with acute symptoms of suspected AE in the early phase. Methods: Eleven consecutive patients with recent acute symptoms suggestive of AE were retrospectively enrolled and underwent brain PET/CT after receiving an intravenous injection of 3.7 MBq/kg of 18F-FDG. Results: PET/CT showed abnormal FDG uptake in 9/11 patients classified as AE, while it was negative in the remaining 2/11 cases with vascular lesions. Magnetic resonance imaging (MRI), conducted in only 10/11 cases—one patient was a pacemaker wearer—identified suspected AE areas in 3/10 cases, ischemic lesions in another 3/10, and nonspecific data in the remaining 4/10 cases. Cerebrospinal fluid (CSF) tests revealed autoantibody delayed occurrence only in three patients (anti-GAD65, anti-Ma2, and anti-LGI1). After first-line treatment, 3/9 patients showed clinical improvement. Another 3/9 patients experienced partial improvement but with recurrence and new AE brain areas identified by PET/CT, which also detected favorable responses to second-line treatment in 2/3 cases. The remaining 3/9 patients, who were not responsive to treatment, ultimately died. Conclusions: In this study, PET/CT was effective in early identification of AE and enabling rapid therapy, even with inconclusive MRI and persistently negative or delayed positive CSF tests. PET/CT may aid in evaluating treatment response and detecting relapse. Notably, a negative PET/CT was associated with AE absence.